Cargando…
1508. Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities
BACKGROUND: UTIs are the most common infection after renal transplant (RTx) with an incidence of 6–86%. Post-RTx UTI has been associated with risk for graft loss and mortality, and RTx recipients are at risk for multidrug-resistant (MDR) UTI given immunosuppression (IS) and instrumentation. We sough...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253264/ http://dx.doi.org/10.1093/ofid/ofy210.1337 |
_version_ | 1783373457966235648 |
---|---|
author | Bohn, Brian Athans, Vasilios Kovacs, Christopher Stephany, Brian Spinner, Michael |
author_facet | Bohn, Brian Athans, Vasilios Kovacs, Christopher Stephany, Brian Spinner, Michael |
author_sort | Bohn, Brian |
collection | PubMed |
description | BACKGROUND: UTIs are the most common infection after renal transplant (RTx) with an incidence of 6–86%. Post-RTx UTI has been associated with risk for graft loss and mortality, and RTx recipients are at risk for multidrug-resistant (MDR) UTI given immunosuppression (IS) and instrumentation. We sought to evaluate the incidence, timing, microbiology, and MDR risk of post-RTx UTI, as well as to characterize asymptomatic bacteriuria (ASB) practices at our center. METHODS: This was a retrospective cohort of subjects with ≥1 positive culture (≥10(5) CFU/mL) during the first year post-RTx that were transplanted from September 1, 2012 to October 1, 2016. Each bacteriuria episode was adjudicated as cystitis, pyelonephritis, or ASB (Figure 1). Subjects without bacteriuria were excluded from primary analysis but used to calculate UTI incidence. The primary outcome was 1-year symptomatic UTI incidence. Secondary outcomes: incidence of cystitis, pyelonephritis, and ASB; time-to-first UTI; microbiologic trends; and presence of MDR risk factors. RESULTS: Baseline characteristics: 52% male, median age 57 years, 65% stented, 34% antithymocyte globulin induction, 94% standard IS regimen (tacrolimus/mycophenolate/prednisone), 93% trimethoprim/sulfamethoxazole prophylaxis, and 21% receipt of IV antibiotics for ≥48 hours within 90 days of first positive culture (IV Abx); Of 527 RTx subjects, 100 had ≥1 positive culture. The 100 subjects had 234 cultures representing 359 isolates. Primary outcome: 12.1% symptomatic UTI incidence. Secondary outcomes (1-year incidences): 18.6% positive culture, 4.3% cystitis, 8.6% pyelonephritis, 11.9% ASB. Time to the first symptomatic UTI was a median of 50 days. A summary of microbiologic results can be found in Figure 2. ASB occurred 130 times and was treated 74.6% of the time (Figure 3). Significant risk factors for MDR UTI included female gender (P = 0.005), IV abx (P = 0.001), and recurrent UTI (P = 0.017). CONCLUSION: Incidence of symptomatic UTI at our center was lower than previous reports. E. coli and E. faecalis were the most common urinary pathogens identified. MDR risk factors identified were biologically plausible and consistent with prior literature. ASB treatment occurred frequently and is an area to target stewardship interventions. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6253264 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62532642018-11-28 1508. Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities Bohn, Brian Athans, Vasilios Kovacs, Christopher Stephany, Brian Spinner, Michael Open Forum Infect Dis Abstracts BACKGROUND: UTIs are the most common infection after renal transplant (RTx) with an incidence of 6–86%. Post-RTx UTI has been associated with risk for graft loss and mortality, and RTx recipients are at risk for multidrug-resistant (MDR) UTI given immunosuppression (IS) and instrumentation. We sought to evaluate the incidence, timing, microbiology, and MDR risk of post-RTx UTI, as well as to characterize asymptomatic bacteriuria (ASB) practices at our center. METHODS: This was a retrospective cohort of subjects with ≥1 positive culture (≥10(5) CFU/mL) during the first year post-RTx that were transplanted from September 1, 2012 to October 1, 2016. Each bacteriuria episode was adjudicated as cystitis, pyelonephritis, or ASB (Figure 1). Subjects without bacteriuria were excluded from primary analysis but used to calculate UTI incidence. The primary outcome was 1-year symptomatic UTI incidence. Secondary outcomes: incidence of cystitis, pyelonephritis, and ASB; time-to-first UTI; microbiologic trends; and presence of MDR risk factors. RESULTS: Baseline characteristics: 52% male, median age 57 years, 65% stented, 34% antithymocyte globulin induction, 94% standard IS regimen (tacrolimus/mycophenolate/prednisone), 93% trimethoprim/sulfamethoxazole prophylaxis, and 21% receipt of IV antibiotics for ≥48 hours within 90 days of first positive culture (IV Abx); Of 527 RTx subjects, 100 had ≥1 positive culture. The 100 subjects had 234 cultures representing 359 isolates. Primary outcome: 12.1% symptomatic UTI incidence. Secondary outcomes (1-year incidences): 18.6% positive culture, 4.3% cystitis, 8.6% pyelonephritis, 11.9% ASB. Time to the first symptomatic UTI was a median of 50 days. A summary of microbiologic results can be found in Figure 2. ASB occurred 130 times and was treated 74.6% of the time (Figure 3). Significant risk factors for MDR UTI included female gender (P = 0.005), IV abx (P = 0.001), and recurrent UTI (P = 0.017). CONCLUSION: Incidence of symptomatic UTI at our center was lower than previous reports. E. coli and E. faecalis were the most common urinary pathogens identified. MDR risk factors identified were biologically plausible and consistent with prior literature. ASB treatment occurred frequently and is an area to target stewardship interventions. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253264/ http://dx.doi.org/10.1093/ofid/ofy210.1337 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Bohn, Brian Athans, Vasilios Kovacs, Christopher Stephany, Brian Spinner, Michael 1508. Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities |
title | 1508. Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities |
title_full | 1508. Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities |
title_fullStr | 1508. Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities |
title_full_unstemmed | 1508. Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities |
title_short | 1508. Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities |
title_sort | 1508. urinary tract infections (utis) in the first year post-renal transplant: risks and opportunities |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253264/ http://dx.doi.org/10.1093/ofid/ofy210.1337 |
work_keys_str_mv | AT bohnbrian 1508urinarytractinfectionsutisinthefirstyearpostrenaltransplantrisksandopportunities AT athansvasilios 1508urinarytractinfectionsutisinthefirstyearpostrenaltransplantrisksandopportunities AT kovacschristopher 1508urinarytractinfectionsutisinthefirstyearpostrenaltransplantrisksandopportunities AT stephanybrian 1508urinarytractinfectionsutisinthefirstyearpostrenaltransplantrisksandopportunities AT spinnermichael 1508urinarytractinfectionsutisinthefirstyearpostrenaltransplantrisksandopportunities |